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Paroxysmal nocturnal hemoglobinuria
(PNH) is characterized by complement-
mediated intravascular hemolysis be-
cause of the lack from erythrocyte sur-
face of the complement regulators CD55
and CD59, with subsequent uncontrolled
continuous spontaneous activation of the
complement alternative pathway (CAP),
and at times of the complement classic
pathway. Here we investigate in an in vitro
model the effect on PNH erythrocytes of a
novel therapeutic strategy for membrane-
targeted delivery of a CAP inhibitor. TT30
is a 65 kDa recombinant human fusion
protein consisting of the iC3b/C3d-binding
region of complement receptor 2 (CR2)
and the inhibitory domain of the CAP
regulator factor H (fH). TT30 completely
inhibits in a dose-dependent manner he-
molysis of PNH erythrocytes in a modi-
fied extended acidified serum assay, and
also prevents C3 fragment deposition on
surviving PNH erythrocytes. The efficacy
of TT30 derives from its direct binding to
PNH erythrocytes; if binding to the eryth-
rocytes is disrupted, only partial inhibi-
tion of hemolysis is mediated by TT30 in
solution, which is similar to that pro-
duced by the fH moiety of TT30 alone, or
by intact human fH. TT30 is a membrane-
targeted selective CAP inhibitor that may
prevent both intravascular and C3-
mediated extravascular hemolysis of PNH
erythrocytes and warrants consideration
for the treatment of PNH patients. (Blood.
2012;119(26):6307-6316)
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a blood disorder
clinically characterized by intravascular hemolysis, thrombophilia,
and bone marrow failure.1-3 A unique feature of PNH is the
presence of clonal populations of blood cells that are defective in
glycosylphosphatidylinositol (GPI)–anchor biosynthesis,4 because
they derive from stem cells harboring an acquired somatic mutation
in the phosphatidylinositol glycan class A (PIG-A) gene.5,6 GPI-
linked surface proteins include CD55 (also known as decay-
accelerating factor [DAF])7,8 and CD59 (or membrane inhibitor of
reactive lysis [MIRL]),9,10 2 major complement regulators on the
cell surface. Because of the lack of these 2 regulators, PNH
erythrocytes (red blood cells [RBCs]) are exquisitely vulnerable to
complement activation. Indeed, the main mechanism of hemolysis
in PNH is the intravascular destruction of CD59 deficient RBCs by
the membrane attack complex (MAC; supplemental Figure 1,
available on the Blood Web site; see the Supplemental Materials
link at the top of the online article).11 MAC formation in patients
can be abrupt and massive when complement is triggered by
specific conditions, as with an infection, explaining the paroxysms
of hemoglobinuria that have given PNH its name. However, at a
lower rate, hemolysis in PNH is continuous, and it is accounted for
by the so-called tickover of the complement alternative pathway
(CAP). Tickover occurs through spontaneous hydrolysis of C3,
binding of factor B to this form of C3, and subsequent formation of
a C3 cleavage and activating multiprotein complex designated a C3
convertase (supplemental Figure 1).12,13 As PNH RBCs are defi-
cient in CD55, both the initial C3 convertase generated by tickover,
as well as the amplification loop of complement (supplemental
Figure 1) are not blocked, allowing unregulated complement
activation on the PNH RBC surface.
Because MAC assembly is triggered by the production of C5b,
a logical approach to preventing intravascular hemolysis in PNH is
the C5 blockade: this has been achieved with the introduction of
eculizumab, an anti-C5 monoclonal antibody (mAb; Soliris, Alex-
ion Pharmaceuticals).14 The clinical results of this novel therapy
have demonstrated that eculizumab is highly effective for PNH
patients.15-19 Although eculizumab protects PNH RBCs from
hemolysis, it does not prevent the initial steps of complement
activation, and consequently in patients treated with eculizumab a
variable proportion (up to 80%) of the PNH RBCs become
opsonized by C3d and probably upstream C3 activation fragments;
and there is evidence that such RBCs may become susceptible to
extravascular hemolysis.20-23 Consequently, targeting the early
steps of complement activation rather than C5 in PNH might
prevent both the MAC-mediated intravascular hemolysis and the
extravascular hemolysis of C3 fragment opsonized RBCs. How-
ever, complete systemic C3 blockade in vivo may prove problem-
atic, because genetic deficiency of C3 in man is associated not only
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with susceptibility to certain infections, but also with immune
complex disease.24
TT30 is a novel recombinant protein that is designed to control
both intravascular and extravascular hemolysis of PNH RBCs.
TT30 is a 65 kDa fusion protein consisting of the iC3b/C3dg-
binding domain of complement receptor 2 (CR2; ie, the short
consensus repeats [SCRs] 1-4), and the CAP inhibitory domain of
factor H (fH; ie, SCR1-5), a complement inhibitor present in
human blood whose primary role is to control fluid phase tickover
(supplemental Figure 2).25 fH selectively inhibits the activation of
CAP and the CAP C3 convertase, without affecting complement
activation and C3 convertase activity arising from the classic
pathway (CCP) and mannose/lectin (CMP) pathway. fH both
prevents formation and promotes the decay of the CAP C3
convertase and also prevents its formation by acting as a cofactor
with factor I (fI) to cleave C3b into the inactive fragment iC3b
(supplemental Figure 1). The CR2 domain of TT30 specifically
targets the fusion protein to sites of complement activation, which
are marked by deposition of C3 fragments including iC3b and C3d.
Thus TT30 is designed to selectively inhibit CAP activation
specifically at sites of complement activation, which in the case of
PNH, is the surface of GPI-deficient RBCs.
In this paper, we show that TT30 is a highly effective inhibitor
of complement-dependent hemolysis of PNH RBCs. Furthermore,
we demonstrate that TT30 blocks CAP activation and prevents C3
fragment opsonization of PNH RBCs. These in vitro studies
suggest that TT30 effectively prevents CAP C3 convertase forma-
tion and can be expected to effectively prevent both intravascular
and extravascular hemolysis in patients with PNH.
Methods
Human samples
Peripheral blood was collected from 32 patients with proven diagnosis of
PNH. Globally, blood samples were available from 21 patients who were
not receiving any anticomplement treatment, and from 12 patients who
were receiving the anti-C5 mAb eculizumab (1 patient was drawn both
before and during eculizumab treatment). Eculizumab was administered
according to the standard schedule15-19 (900 mg every 14  2 days, after a
loading phase of 600 mg every 7  1 days for 4 doses). Blood was collected
in standard ethylenediaminetetraacetic acid (EDTA) and serum vacutainer
tubes (BD Pharmingen; Becton Dickinson Italia) after venipuncture accord-
ing to standard procedures, after informed consent in accordance with the
Declaration of Helsinki as approved by the Federico II University
institutional review board. Blood was usually collected at the time of
venipuncture for standard laboratory testing, with the exception of some
PNH patients on eculizumab, from whom blood was also drawn within
60 minutes of eculizumab administration (as source for serum containing
eculizumab). In addition, blood was collected from 10 healthy individuals
as a source for ABO-matched normal sera.
RBC and serum preparation
After collection of peripheral blood samples, RBCs were obtained from
EDTA tubes after centrifugation (5 at 350g) and 3 washings in saline, to
prepare a final 50% RBC resuspension (approximately 5  106 cells/L).
For midterm storage, RBCs were resuspended at 50% in hypertonic
saline-adenine-glucose-mannitol (SAG-M) solution (hemapheresis bags
from Fresenius-Kabi Italy) and stored at 4°C up to 4 weeks. Fresh sera were
obtained from serum tubes after immediate centrifugation (15 at 1350g); sera
were used within 1 hour, or stored at80°C for subsequent use. In experiment
with normal sera, a pool from at least 2 healthy subjects was used, to prevent
biases because of inter-patient variability in complement activity.
The extended acidified serum assay
C3 tickover and CAP activation is accelerated by serum acidification, and it
was exploited in our in vitro assay to investigate the effect of TT30 on
complement pathways in PNH. Starting from the standard diagnostic
acidified serum assay (Ham test), a modified assay was developed to
provide a model that allows for in vitro investigation of both early
CAP-directed activation as well as terminal complement cascade activation
on the PNH RBC surface, which leads to C3 fragment deposition and
MAC-mediated hemolysis, respectively. This assay provides a surrogate
model for chronic, continuous, complement activation through the tickover
mechanism, which leads to hemolysis of PNH cells. It also serves as a
model for in vitro C3-deposition on PNH RBCs in the presence of terminal
complement inhibition by eculizumab. For this purpose, RBCs from PNH
patients were incubated at final hematocrits of 2% (or 16% and 33%, in
selected experiments) with sera (either from ABO-matched healthy indi-
vidual or PNH patients on eculizumab) supplemented by MgCl2 (at a final
1.5mM concentration). CAP activation was achieved by lowering the pH,
through addition of HCl (1:20 of HCl 0.1N); the final pH ranged between
6.7 and 6.9. The complement inhibitor TT30 (or controls) were added to the
tubes at different concentration before complement activation. Tubes were
incubated at 37°C for 24 hours, with the RBC pellet analyzed for hemolysis
and C3-deposition at specific time-points at 1 and 24 hours.
Assessment of hemolysis and C3 fragment deposition
Hemolysis of PNH RBCs and C3-deposition on the RBC surface were
assessed by flow cytometry, as previously described.20,26-28 In brief, 1 L of
the RBC pellet was resuspended in 1 mL of saline; the resulting suspension
(approximately 104 RBCs/L) was incubated with either a phycoerythrin
(PE)–conjugated or an allophycocyanin (APC)–conjugated anti-CD59
(59PE or 59APC Valter Occhiena, used 1:10 and 1:25, respectively), and a
fluorescein isothiocyanate (FITC)–conjugated anti-C3 polyclonal antibod-
ies (Ab14396 Abcam; a 1:20 working solution from the original tube was
used at a final dilution of 1:50). Samples were incubated at room
temperature for 1 hour, and then analyzed with a FACScan cytometer
(Becton Dickinson Italia), after dilution by adding 10 volumes of saline (or
FACS flow, Becton Dickinson Italia).20 The percentage of type III PNH
(CD59) and of normal (N, CD59) RBCs was derived from RBC pellets
incubated in different conditions, as well as from baseline samples;
hemolysis was measured by comparing baseline (pre) and postincubation
(post) percentage of PNH RBCs. The proportion of surviving PNH RBCs
(%PNH post/%PNH pre) was normalized, based on the determination of
residual normal RBCs (dividing by %N post/%N pre); the rate of hemolysis
was then calculated as the reciprocal of the percentage of survival. This
finally leads to the formula previously published by Ferreira et al26:
%lysis  100  (%PNH post/%N post)  (%N pre/%PNH pre)  100.
C3-deposition was expressed as both percentage of C3 PNH RBCs
[(%C3/%PNH)  100] at specific time-points and percentage C3-deposition
from initial PNH RBCs, according to the following formula: %C3-
deposition (%C3/%PNH)  %survival (where survival [%PNH post/%N
post] [%N pre/%PNH pre] 100).27,28
Kinetics of distinct C3-fragment deposition and processing
The RBC pellet obtained as described in “RBC and serum preparation” was
also incubated with different anti-C3 mAb, which have a known specificity
for either C3b/iC3b or C3dg/C3d. They include the anti-C3dg/C3d mAbs
1H8 and 14H10, as well as the anti-C3b/iC3b mAbs 2C5, 3C11, 3E7, 7C12,
and 8E11; the specificity of all these antibodies has been described
elsewhere.29 Counter-staining was accomplished with either the APC-
conjugated anti-CD59 mAb or, in selected experiments, with a PE-
conjugated anti-glycophorin A (GPA) mAb (Becton Dickinson Italia; used
1:25); this latter was used to identify RBC ghosts. To investigate the
concomitant presence of C3b/iC3b and C3dg/C3d fragments a biotinylated
anti-C3d was also used (A702, Quidel); A702 was used 1:10 with RBC
suspension, and detected by either PE or APC-conjugated streptavidin
(Becton Dickinson Italia; used 1:20 after RBC washing). Samples were
incubated at room temperature for 1 hour, and analyzed as described
“Assessment of hemolysis and C3 fragment deposition.”
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Complement inhibitors
TT30 was provided by Alexion (formerly Taligen Therapeutics) as frozen
160M stocking solution. The vials were stored at80°C, and held at room
temperature 1 hour before the experiments. Working solutions of 120M
and further appropriate dilutions were obtained by adding adequate
volumes of PBS. As a negative control, we used: (1) recombinant fH
SCR1-5 (Alexion Pharmaceuticals); (2) CR2 SCR1-4 (Alexion Pharmaceu-
ticals); and (3) human purified fH (A137 Complement Technology); they
were used at concentration equimolar to TT30 (1M). In addition, an
anti-CR2 mAb (mAb 1048, Green Mountain Antibody), which specifically
inhibits the binding of CR2 (and thus of TT30) to C3 fragments was used in
blocking experiments.30 As an in vitro surrogate of eculizumab use, sera
from patients on eculizumab were used. Such sera were collected within
60 minutes of eculizumab administration, at an expected peak concentra-
tion of at least 200 g/mL.15 This eculizumab concentration is approxi-
mately 1 log higher than the minimal inhibitory concentration.15
TT30 binding
TT30 binding was assessed by flow cytometry using 2 different FITC-
conjugated mAbs specific for either fH (Valter Occhiena) or CR2 (HB5,
Santacruz Biotechnology; HB5 is known to not interfere with C3 fragment
binding to CR2).31 These mAbs bind the 2 different portions of the fusion
protein TT30. Both mAbs were used 1:10 with the RBC suspension
(prepared by diluting the RBC pellet 1:1000 in saline), and incubated 1 hour
at room temperature. A counter-staining with the anti-CD59 (either PE or
APC-conjugated) and the biotinylated anti-C3d A702 (detected by either
PE or APC-conjugated streptavidin, see above) was used to assess the
colocalization of TT30 and C3frag on PNH RBCs.
Statistical analysis
Standard descriptive statistical measures were used to analyze the rate of
hemolysis and C3 deposition.
Results
TT30 abrogates hemolysis of PNH RBCs in the extended
acidified serum assay (EASA)
We have developed an experimental method to examine CAP-
mediated early and terminal complement activation on PNH RBCs.
In the EASA, RBCs obtained from PNH patients were incubated
for 24 hours at 37°C in ABO-matched normal human serum (NHS)
in which complement activation was promoted by lowering the pH.
CAP activation results in progressive lysis of the majority of PNH
RBCs, as assessed by flow cytometric analysis of the residual RBC
pellet,26 regardless of whether the samples were from untreated or
eculizumab-treated patients (80.2  2.8 and 86.6  2.1, respec-
tively; Figure 1). This indicates that the system produces hemolysis
whether or not RBCs have C3 on their membrane. With RBCs from
untreated PNH patients, preincubation of NHS with TT30 resulted
in a concentration-dependent reduction of hemolysis, which was almost
complete (5 1.1%) at a TT30 level of 3M (Figure 1A). Similar
results were obtained using RBCs from PNH patients on eculizumab
(Figure 1B); in some cases we observed a minimal hemolysis, which
was probably the result of a build up of C5 convertase which may have
taken place in vivo as a consequence of C3b deposition.
Kinetics of C3 fragment deposition and processing in the EASA
The early stages of CAP activation and hemolysis were investi-
gated as a function of time by flow cytometric analysis of the pellet
of unlysed RBCs. With RBCs from untreated PNH patients (Figure
2A-D), after 1 hour incubation in aNHS we found that: (1) the
proportion of PNH RBCs is significantly reduced, consistent with
selective lysis of PNH RBCs (Figure 2F); (2) Of the few surviving
PNH RBCs, most have no C3b/iC3b or C3d deposition (Figure
2F-H); and (3) RBC ghosts (the intact membrane of lysed RBC,
identified by physical parameters: Figure 2E and by glycophorin A
staining, data not shown) are CD59 negative (PNH phenotype) and
have bound both C3b/iC3b and C3d fragments (Figure 2F-H),
consistent with complement-mediated lysis of the PNH RBCs. At
24 hours all PNH RBCs had been lysed (Figure 2I-L).
When similar experiments were carried out using fresh serum
containing eculizumab (obtained from PNH patients on eculi-
zumab, aEcuHS) we observed substantial inhibition of lysis: most
PNH RBCs remain intact, and progressively accumulate C3
fragments on their surface. Initially both C3b/iC3b and C3d
fragments were detected (Figure 2M-P); gradually, over a 24 hour
interval, these were converted into C3d (Figure 2Q-T). This
experiment recapitulates the observation of C3 fragment deposition
in vivo on PNH RBC in patients on eculizumab.20 These findings
provide further evidence supporting the role of CAP activation in
the C3 fragment opsonization and lysis of PNH RBCs.
TT30 inhibits C3 fragment deposition on PNH RBCs
Having found that EASA enables us to analyze early CAP
activation on PNH RBCs, we next investigated how this process is
Figure 1. Effect of TT30 on hemolysis of PNH RBCs from untreated and eculizumab-treated PNH patients in the EASA. (A) PNH patients not on eculizumab. Absolute
percentage lysis of PNH RBCs in aNHS with and without TT30. Lines represent the mean values of 26 experiments (10 in duplicate, 1 in triplicate, and 3 in quadruplicate) on
RBCs obtained from 14 untreated PNH patients (2 patients were drawn 4 times, 3 patients drawn 3 times, and the remaining 9 just once); error bars represent SEM. The
continuous thin black line indicates aNHS; dashed thin black line, TT30 0.3M; dashed bold black line, TT30 1M; and continuous bold black lines, TT30 3M. (B) PNH
patients on eculizumab. Absolute percentage lysis of PNH RBCs in aNHS with and without TT30. Lines represent the mean values of 26 experiments (12 in duplicate, 1 in
triplicate, and 3 in quadruplicate) on RBCs obtained from 6 PNH patients on eculizumab treatment (1 patient was drawn 14 times, 1 patient drawn 9 times, and the remaining
3 just once); error bars represent SEM. The continuous thin black line indicates aNHS; dashed thin black line, TT30 0.3M; dashed bold black line, TT30 1M; and continuous
bold black lines, TT30 3M.
TT30 INHIBITS HEMOLYSIS AND C3 OPSONIZATION IN PNH 6309BLOOD, 28 JUNE 2012  VOLUME 119, NUMBER 26
affected by TT30. We first made sure that TT30, even at a level of
30M, did not interfere with the detection of either C3b/iC3b or
C3d by the anti-C3 mAbs used in this study. In brief, PNH RBCs
obtained from eculizumab-treated patients (with known proportion
of C3 RBCs) were preincubated 1 hour with TT30 30M, and
then stained with our set of anti-C3b/iC3b and anti-C3d mAb (as
well as with the polyclonal anti-C3). The proportion of C3 RBCs
did not change after the preincubation with TT30, nor did the
intensity of fluorescence decrease (supplemental Figure 3). Then
we found that after 1 to 24 hours incubation in aNHS  3M
TT30, PNH RBCs from untreated patients did not show C3
fragment deposition by flow cytometric analysis (Figure 3A-H).
Notably, even the very early product of CAP activation, C3b/iC3b,
was not detectable at any time point on PNH RBCs. Prevention of
lysis and of C3 fragment deposition is consistent with a complete
blockade of both CAP C3 and C5 convertase activity. Similar
Figure 2. Kinetics of C3 fragment deposition and processing in the EASA. (A-D) Fresh PNH RBCs from untreated patient, baseline data. (A) Forward scatter (y-axis)
versus side scatter (SSC). (B) CD59 APC (y-axis) versus C3b/iC3b FITC (x-axis; mAb 7C12). (C) CD59 APC (y-axis) versus C3d biotinylated-streptavidin PE (x-axis; mAb
A702); (D) C3d biotinylated-streptavidin PE (y-axis) versus C3b/iC3b FITC (x-axis; mAb 3E7). Red and blue dots represent intact RBCs and RBC ghosts, respectively, as gated
based on physical parameters (panels A-E). (E-L) aNHS. (E-H) C3b/iC3b and C3d deposition at 1 hour. (I-L) C3b/iC3b and C3d deposition at 24 hours. (E-I) forward scatter
(y-axis) versus SSC. (F-J) CD59 APC (y-axis) versus C3b/iC3b FITC (x-axis; mAb 7C12). (G-K) CD59 APC (y-axis) versus C3d biotinylated-streptavidin PE (x-axis; mAb
A702); (H-L) C3d biotinylated-streptavidin PE (y-axis) versus C3b/iC3b FITC (x-axis; mAb 3E7). Red and blue dots represent intact RBCs and RBC ghosts, respectively, as
gated based on physical parameters (panels E-I). (M-T) aEcuHS. (M-P) C3b/iC3b and C3d deposition at 1 hour. (Q-T) C3b/iC3b and C3d deposition at 24 hours. (M-Q) forward
scatter (y-axis) versus SSC. (N-R) CD59 APC (y-axis) versus C3b/iC3b FITC (x-axis; mAb 7C12). (O-S) CD59 APC (y-axis) versus C3d biotinylated-streptavidin PE (x-axis;
mAb A702); P, T: C3d biotinylated-Streptavidin PE (y-axis) versus C3b/iC3b FITC (x-axis; mAb 3E7). Red and blue dots represent intact RBCs and RBC ghosts, respectively, as
gated based on physical parameters (panels M-P).
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results were obtained by inhibiting the CAP C3 convertase with the
anti-C3b mAb 3E7 (Figure 3I-P), which is known to completely
prevent C3 activation on PNH RBCs.32
Membrane targeting of TT30 by the CR2 domain is required for
full inhibition of hemolysis
To verify that the CR2 moiety is crucial for the action of TT30, we
used the anti-CR2 mAb 1048, which binds to the C3-binding
domain of CR2 and is known to directly inhibit the binding of CR2
(and thus of TT30) to C3 fragments.33 Indeed, mAb 1048 at a molar
concentration 3 times higher than TT30 markedly decreases the
protection from hemolysis by TT30 (hemolysis of RBCs from
untreated PNH patients was 49.4  6.2%; Figure 4A). Similar
results were obtained when RBCs from eculizumab-treated PNH
patients were studied (hemolysis 56.1  6.2%; supplemental Fig-
ure 4A). Interestingly, in the presence of excess mAb 1048, the
residual effect of TT30 was quantitatively similar to that of an
equimolar concentration of purified human fH (Figure 4A, supple-
mental Figure 4A). Furthermore, similar degree of inhibition was
also observed using recombinant fH SCR1-5 (Figure 4A, supple-
mental Figure 4A), whereas CR2 SCR1-4 did not produce any
inhibition of hemolysis (Figure 4A, supplemental Figure 4A). This
result suggests that the residual partial inhibitory effect of TT30 was
probably attributed to the fH moiety of TT30 acting in the fluid phase.
Dose-response curve of TT30 on hemolysis at different
hematocrits
Given the unique mechanism of action of TT30, its effects in vivo
might depend not only on its level in the plasma but also on the
mass of RBCs that are the actual target of TT30. Therefore it was
important to test whether the effect of TT30 varies as a function of
the hematocrit value. We found that the dose-response curves were
essentially the same at hematocrits of 2%, 16%, or of 33%, which is
rather near a normal hematocrit in vivo, with an IC50 of approxi-
mately 0.5M (Figure 4B). Similar results were obtained with
RBC from eculizumab-treated patients (supplemental Figure 4B).
TT30 binds to PNH RBCs in the EASA
To further confirm that TT30 exerts a local regulatory effect on the
RBC membrane, we examined TT30 binding to PNH RBCs using
Figure 3. TT30 inhibits C3 fragment deposition on PNH RBCs in the EASA. (A-H) aNHS TT30 3M. (A-D) C3b/iC3b and C3d deposition at 1 hour. (E-H) C3b/iC3b and
C3d deposition at 24 hours. (A-E) forward scatter (y-axis) versus side scatter (SSC). (B-F) CD59 APC (y-axis) versus C3b/iC3b FITC (x-axis; mAb 7C12). (C-G) CD59 APC
(y-axis) versus C3d biotinylated-streptavidin PE (x-axis; mAb A702); (D-H) C3d biotinylated-streptavidin PE (y-axis) versus C3b/iC3b FITC (x-axis; mAb 3E7). Red and blue
dots represent intact RBCs and RBC ghosts, respectively, as gated based on physical parameters (panels A-E). (I-P) aNHS3E7 2M. (I-L) C3b/iC3b and C3d deposition at
1 hour. (M-P) C3b/iC3b and C3d deposition at 24 hours. (I-M) forward scatter (y-axis) versus SSC. (J-N) CD59 APC (y-axis) versus C3b/iC3b FITC (x-axis; mAb 7C12).
(K-O) CD59 APC (y-axis) versus C3d biotinylated-streptavidin PE (x-axis; mAb A702); (L-P) C3d biotinylated-streptavidin PE (y-axis) versus C3b/iC3b FITC (x-axis; mAb 3E7).
Red and blue dots represent intact RBCs and RBC ghosts, respectively, as gated based on physical parameters (panels I-M).
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2 mAbs: (1) an anti-fH that recognizes the CAP-inhibitory domain
of TT30; and (2) an anti-CR2 that recognizes the C3 fragment-
binding domain of TT30 (and was previously shown not to
interfere with C3-CR2 binding).30 Because we know that TT30
prevents C3 deposition in vitro, we used in these experiments
RBCs freshly obtained from PNH patients on eculizumab, a
substantial fraction of which are covalently tagged with C3
fragments in vivo (see Figure 2). After 1 hour incubation in aNHS
with 1 to 3M TT30 we found that a similar proportion of RBCs
had become positive for the anti-fH and the anti-CR2 mAbs: we
infer that these antibodies were recognizing TT30 on the RBC
surface (Figure 5D-E). By counter-staining for CD59, we were able
to prove that TT30 binding was restricted to PNH (CD59) RBCs
(Figure 5D-E). Consistent with a C3 fragment targeting mecha-
nism, the extent of TT30 binding correlated with the amount of C3d
on PNH RBC surface (Figure 5D-E). In addition, preincubation
with anti-CR2 mAb 1048, which blocks CR2 binding to iC3b/C3d
but does not interfere with the detecting anti-CR2 mAb (data not
Figure 4. Abrogation of TT30 inhibition of hemolysis and dose-response curve at different hematocrits; PNH patients not on eculizumab. (A) Abrogation of TT30
effect by the blocking anti-CR2 mAb 1048 and comparison with human recombinant fH. Absolute percentage lysis of PNH RBCs in aNHS with and without TT30  the blocking
anti-CR2 mAb 1048, or with the human recombinant fH (1M), the human fH SCR1-5 (fH portion of TT30, 1M) or the human CR2 SCR1-4 (CR2 portion of TT30, 1M).
Histograms represent the mean values of 6 experiments (4 in duplicate) on RBCs obtained from 4 untreated PNH patients; error bars represent SEM. (B) dose-response curve
of TT30 on hemolysis at different hematocrits. Lysis (y-axis) of PNH RBCs according to TT30 concentration (x-axis); lysis is expressed as relative percentage of the lysis
observed without any inhibitor (in each experiment, 100% represent the lysis observed in aNHS). Curves represent the mean of 14 experiments performed on samples
obtained from 7 PNH patients (1 was drawn 4 times, 1 drawn 3 times, and 2 drawn twice), at different percentage of hematocrits. The continuous black line indicates hematocrit
2%; continuous gray line, hematocrit 16%; and dashed black line, hematocrit 33%. Error bars represent SEM.
Figure 5. Detection of membrane-bound TT30 on PNH RBCs from an eculizumab-treated PNH patient. RBCs from a PNH patients on eculizumab were incubated 1 hour
in aNHS with or without TT30 ( the anti-CR2 blocking mAb 1048); TT30 was detected by using either an anti-fH mAb (panels B,D,F,H) or an anti-CR2 mAb (C,E,G,I), both
FITC-conjugated. The biotinylated anti-C3d mAb A702 was used to detect C3d (with APC-streptavidin); an APC-conjugated anti-CD59 was used to identify PNH RBCs.
(A) Gating strategy on PNH RBCs. RBCs from an eculizumab-treated patient were used for this experiment; CD59 APC (y-axis) versus side scatter (SSC). PNH RBCs were
identified by CD59 expression, and gated accordingly for further analysis of TT30 binding. (B-C) TT30 binding on fresh RBCs. Fresh PNH RBCs have a substantial C3d
deposition, but do not show any cross-binding with the anti-fH or anti-CR2 mAb (B-C, respectively). C3d biotinylated-Streptavidin PE (y-axis; mAb A702) versus either fH or
CR2-FITC (x-axis; B-C, respectively); analysis on CD59 RBCs (gate as shown in panel A). (D-E) TT30 binding after exposure in aNHS  TT30. After in vitro exposure to
aNHS TT30 3M, TT30 can be detected on PNH (CD59) RBCs by both the anti-fH (D) and the anti-CR2 (E). The saber-like pattern indicates the colocalization of C3d and
TT30 on PNH RBC surface, with the most pronounced bound-TT30 detected on RBCs with the most abundant C3d deposition. C3d biotinylated-Streptavidin PE (y-axis; mAb
A702) versus either fH or CR2-FITC (x-axis; D-E, respectively); analysis on CD59 RBCs (gate as shown in panel A). (F-G) TT30 binding after blocking by the anti-CR2 mAb
1048. Preincubation of TT30 with a 3-fold excess of the anti-CR2 mAb 1048 (TT30 1M and mAb 1048 3M) abrogates TT30 binding on PNH RBCs. C3d
biotinylated-Streptavidin PE (y-axis; mAb A702) versus either fH or CR2-FITC (x-axis; F-G, respectively); analysis on CD59 RBCs (gate as shown in panel A).
6312 RISITANO et al BLOOD, 28 JUNE 2012  VOLUME 119, NUMBER 26
shown), completely prevented TT30 binding, confirming that the
TT30 binding is mediated by its CR2 moiety recognizing C3
fragments on the surface of PNH RBC (Figure 5F-G).
Discussion
TT30 is a 65 kDa fusion protein (supplemental Figure 2)34
consisting of (1) the iC3b/C3dg-binding domain of the C3 frag-
ment receptor CR2 (SCR1-4), which will bind to iC3b and to C3d
on red cells; and (2) the complement inhibitory domain of fH
(SCR1-5),35,36 an inhibitor of CAP activation. The fH moiety of
TT30, like fH itself, can both accelerate the decay of the CAP C3
convertase by displacing the Bb peptide from C3b, and act as a cofactor
for the inactivation of C3b by the serine protease factor I (fI).
In this study, we tested extensively the efficacy of TT30 in
preventing CAP activation and subsequent hemolysis of PNH
RBCs. We modeled in vitro 2 important steps of what appears to
occur in PNH patients in vivo: first, initial complement activation,
resulting in C3 fragment opsonization of PNH RBCs, which may
be a surrogate for C3-mediated extravascular hemolysis; second,
terminal effector complement activity, resulting in hemolysis in
vitro, as a surrogate for MAC-mediated intravascular hemolysis. In
vivo, C3 fragment deposition becomes evident during eculizumab
treatment when intravascular hemolysis is blocked.20-22,37 We
reproduced this phenomenon in an in vitro system using sera from
PNH patients treated with eculizumab. Eculizumab resulted in
progressively increasing deposition of C3b/iC3b and eventually
conversion to C3d on all PNH RBCs (paralleling our previous in
vivo observations).20 In vitro TT30 produced dose-dependent
inhibition of both C3 fragment deposition and hemolysis with an
IC50 of 0.5M (32 g/mL).
Reproducing in vitro what we have already found in vivo was
an essential step for the experimental study of the mechanism of
action of TT30. To pinpoint the site of TT30 action, we tested
specifically for a membrane-bound effect versus a fluid phase
effect. An anti-CR2 mAb, which interferes with the binding of the
CR2 domain of TT30 to the iC3b/C3d target on RBCs, substan-
tially reduced its protective effect on lysis of PNH RBCs. After
TT30 binding to PNH RBCs is prevented by this antibody, it still
has a residual capacity to inhibit hemolysis: this capability is
similar to that of an equimolar concentration of human purified fH.
Moreover, the fH moiety on its own has a similar effect; and we
noted that the concentration that we have used is approximately
5 times lower than the physiologic concentration of fH in normal
plasma (500-800 g/mL)38; the concentration of fH may be
somewhat higher in PNH patients.39 TT30 was designed deliber-
ately to target selectively the cell membrane as the site of
complement activation,34 and our data indeed suggest that TT30
targeting to the cell membrane is required for full inhibitory effect.
We demonstrated that TT30 is physically present on the RBC
surface by taking advantage of the fact that a substantial proportion
of PNH RBCs in eculizumab-treated patients are covalently tagged
with C3d. In addition, we demonstrated that TT30 binds to these C3
fragments through the CR2 domain, as mAb 1048, which is known
to disrupt CR2-C3d binding, also abrogates TT30 binding to
C3d-coated RBC. TT30 binding was not demonstrated on RBCs of
patients who were not on eculizumab and in whom C3d is not
detectable on PNH RBCs. We presume that in blood samples from
these patients there is a steady state whereby very few molecules of
TT30, undetectable by flow cytometry, are sufficient to prevent the
formation of C3 convertase and therefore sufficient to prevent
complement activation that is ongoing.
TT30, by supplying the function of fH, is able to act as a
cofactor for fI to convert nascent C3b into iC3b, thus generating
more of its own target and disabling the CAP amplification loop. At
the same time, on PNH RBCs TT30 serves a surrogate for the
function of the CD55 that is missing; thus, it prevents formation
and promotes decay of the CAP C3 convertase by displacing factor
B and factor Bb, respectively, from the C3b-bound state. This result
is in keeping with the previous finding that competitive inhibition
of fH binding through the use of a decoy peptide markedly
increases the in vitro lysis of PNH red cells.26 Taken together, these
data support the notion that, whether C3 is activated in vitro by
lowering the pH, or in vivo through the CAP C3 tickover, very few
TT30 molecules per RBC are sufficient to prevent further signifi-
cant activation of C3 (Figure 6). Because, in vivo, the number of
PNH RBCs that need to be protected is huge, it is important in
terms of clinical translation, that we have found that TT30 is
effective at the same concentration even with a hematocrit of 33%.
It was recently shown in a cynomolgus monkey model that TT30 is
bioavailable by both intravenous (IV) injection and subcutaneous
injection, leading to plasma levels sufficiently high to prevent
CAP-mediated (but not CCP-mediated) MAC formation in sera
drawn from treated animals.34 Effective plasma levels were sus-
tained for 8 hours after IV injection and 24 hours after subcutane-
ous injection; the half-life was not formally established, and it may
not be informative because patients will have an individually
variable biodistribution because of increased (C3) cells and
tissue targets. From our current data it is hard to predict what
plasma levels in vivo in PNH patients will be needed for a complete
prevention of hemolysis, because our in vitro hemolytic assay
employs supraphysiologic complement activation. Thus, pharmaco-
kinetic and pharmacodynamic data will have to be assessed in
humans, especially in the context of systemic or tissue-specific
dysregulated complement activation, such as in PNH or other
CAP-mediated diseases.
Our view of complement modulation on PNH RBCs by
different complement inhibitors is somewhat in contrast with
previous (but limited) observations on RBCs from patients with
isolated CD55 (the so-called Inab phenotype)40 or CD59 defi-
ciency.41 Indeed, on PNH RBCs use of eculizumab results in a
functional replacement of CD59, but C3 deposition and subsequent
extravascular hemolysis have not been observed in Inab patients in
vivo.42 However, it has been reported that C3 opsonization in vitro
is increased on Inab RBCs once CD59 is specifically inhibited by a
blocking mAbs,43 suggesting a possible additional direct or indirect
role for CD59-mediated MAC inhibition in the “upstream” regula-
tion of the C3 convertase (in addition to its classic role in defending
the membrane from the MAC). Our previous20 and current findings
support this hypothesis. On the other hand, although in our in vitro
model functional replacement of CD55 by TT30 is sufficient to
prevent hemolysis, isolated deficiency of CD59 resulted in vivo in
a clinical phenotype that overlaps with PNH.41 Therefore one may
argue that in modulating C3 convertase activity TT30 is more
efficient than CD55, as the former seems to keep the rate of
formation of C5b low enough to control MAC generation even
when CD59 is lacking. Taken together, these observations highlight
the fact that even in the presence of specific anticomplement agents
the phenotype of PNH remains unique: it is not a mimic of any
known inherited condition.
Any attempt to interfere with the complement cascade for
therapeutic purposes must come to terms with the potential risks
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that a selective blockade of 1 or more elements of the complement
system might entail.44-46 Inherited defects of complement proteins
are informative in this regard.47 For example, an inherited defi-
ciency of C3 in humans has a much more severe clinical phenotype
than an inherited deficiency of C5, including not only severe
infection (from capsulated or pyogenic organisms) but also im-
mune complex diseases.24 Furthermore, inactivating mutation of
factor B have been associated with glomerulonephritis in a few
heterozygous patients,48 even if factor B knockout mice have not
yet shown a specific disease phenotype.47,49 Thus, at the clinical
level we are faced with a dilemma: systemic blockade of C5 is
effective in preventing MAC formation, but not in preventing
proximal CAP activation, which may lead to C3 fragment deposi-
tion on PNH RBC and extravascular hemolysis; on the other hand,
systemic blockade of C3, which would prevent C3 fragment
opsonization of PNH RBCs, may carry a risk of other complica-
tions. An anti-C3 mAb was recently developed that blocks the CAP
and is specific for C3 fragments (C3b/iC3b), as opposed to intact
C3.32 Although this approach has proven successful in an in vitro
PNH model, it may be problematic in that it may predispose to
immune complex disease, and may lead to further opsonization
through the membrane-bound anti-C3 fragment mAb, and thus fail
to overcome the problem of extravascular hemolysis. In contrast,
TT30 is designed to selectively inhibit the CAP only, and in a
targeted fashion, that is, on the surface of PNH RBC rather than
systemically: this may improve its safety profile. Inherited polymor-
phisms or mutations in fH have been associated with a variety of
complement-mediated diseases,50 such as atypical hemolytic-
uremic syndrome,51 age-related macular degeneration,52 and dense
deposit disease.53 However, all of these conditions result from
loss-of-function mutations.50 On account of its structure TT30 may
be regarded rather as a gain-of-function mutation (none of which
are known): therefore we argue that there is not a priori reason why
it ought to predispose to any complement-mediated disease. A
Figure 6. Complement cascade modulation on normal and PNH RBCs, with or without complement inhibitors. (A) Normal RBCs, steady state. Normal RBCs (CD55,
CD59) are protected from complement activation by CD55, which down-regulate the C3-convertase, and by CD59, which inhibits the MAC assembly. Thus, in steady state
normal RBCs can withstand the challenge of complement activation. (B) PNH RBCs, steady state. PNH RBCs (CD55, CD59) suffer from impaired complement regulation at
the level of both C3-activation (because of the lack of CD55) and MAC assembly (because of the lack of CD59). As a result, in steady state, PNH RBCs eventually undergo
intravascular hemolysis because of complement activation. (C) PNH RBCs, on eculizumab. On eculizumab treatment, PNH RBCs are protected from lysis because of the
blockade of terminal effector complement; however, because of the impaired C3-convertase regulation, they suffer from continuous complement activation and subsequent
membrane deposition of C3 fragments. As a result, on eculizumab, PNH RBCs may become susceptible to extravascular hemolysis secondary to removal of C3-opsonized
RBCs by reticuloendothelial system (RES) macrophages, resulting in possible reduced life-span PNH RBCs. (D) PNH RBCs, on TT30. As soon as complement activation is
initiated, the CR2-domain of TT30 delivers the complement-modulatory domain of fH to the RBC surface. Then, TT30 disables the C3-convertase, and, as cofactor of factor I, it
promotes the conversion of active C3b into iC3b and then C3dg/C3d, preventing all downstream events because of the complement cascade (as well as additional complement
activation on the red cell membrane). As a result, irrespective of the blockade of C5, TT30 may confer to PNH RBCs a normal survival even in presence of complement
activation.
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murine analog of a CR2/fH and other CR2-targeted fusion proteins
have proven effective in various models of complement-mediated
diseases,54-56 with little toxicity (in particular, without any increase
in mortality in a model of acute septic peritonitis).47 In humans, we
may anticipate that TT30, because of its CAP-selective and
membrane-preferential action, may preserve physiologic immune-
complex clearance and microorganism elimination, while fully
abrogating hemolysis of PNH RBCs.
We must also recognize that a possible activation of the
complement pathway through the CCP or the CMP can limit the
clinical efficacy of TT30 in certain situations, especially in consideration
of the build up of PNH RBCs. For instance, during infectious-related
paroxysms CCP or CMP may contribute to hemolysis, in addition to the
direct CAP activation on PNH RBCs by bacterial lipopolysaccharides.
However, we must recall that CAP is required to amplify any initial
complement activation, eventually contributing for optimal operation
also of the other 2 complement pathways.46,57 Therefore, hemolysis of
PNH RBCs requires a functional CAP, and the risk of catastrophic
hemolytic crises during TT30 treatment seems low; however, it remains
a potential limitation which has to be addressed in future in vivo studies.
In conclusion, we report a novel strategy to deliver specific
inhibition of the CAP at the cell membrane level, which appears
promising for PNH and may be relevant also for other complement-
mediated diseases.58 Our experiments support the notion that TT30
targets C3 fragments on PNH RBCs to deliver surface-based fH
activity. Thus, by blocking the CAP and its amplification loop, the
CR2/fH fusion protein TT30 inhibits both intravascular hemolysis
and C3 fragment opsonization of PNH RBCs. Our preclinical data
provide a strong rationale for testing TT30 in PNH patients; indeed,
TT30 is now under investigation in a phase 1 clinical trial enrolling
untreated PNH patients (NCT01335165).59
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